The New Challenge of Obesity - Obesity-Associated Nephropathy
DOI: https://doi.org/10.2147/dmso.s433649
2024-05-06
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Mengjin Hao, 1, 2 You Lv, 1 Siyuan Liu, 1 Weiying Guo 1 1 Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, 130021, People's Republic of China; 2 Department of Endocrinology, Jining No. 1 People's Hospital, Jining, Shandong, 272000, People's Republic of China Correspondence: Weiying Guo, Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, People's Republic of China, Email In recent years, obesity has become one of the major diseases that affect human health and consume human health resources, especially when it causes comorbidities such as hypertension, diabetes, cardiovascular disease and kidney disease. Many studies have demonstrated that obesity is associated with the development of chronic kidney disease and can exacerbate the progression of end-stage renal disease. This review described the mechanisms associated with the development of obesity-associated nephropathy and the current relevant therapeutic modalities, with the aim of finding new therapeutic targets for obesity-associated nephropathy. The mechanisms of obesity-induced renal injury include, in addition to the traditional alterations in renal hemodynamics, the involvement of various mechanisms such as macrophage infiltration in adipose tissue, alterations in adipokines (leptin and adiponectin), and ectopic deposition of lipids. At present, there is no "point-to-point" treatment for obesity-induced kidney injury. The renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-dependent glucose transporter 2 (SGLT-2) inhibitors and bariatric surgery described in this review can reduce urinary protein to varying degrees and delay the progression of kidney disease. In addition, recent studies on the therapeutic effects of intestinal flora on obesity may reduce the incidence of obesity-related kidney disease from the perspective of primary prevention. Both of these interventions have their own advantages and disadvantages, so the continuous search for the mechanism of obesity-induced related kidney disease will be extremely helpful for the future treatment of obesity-related kidney disease. Keywords: obesity, kidney injury, inflammation, oxidative stress, adiponectin, leptin Obesity has become a world health problem that affects health. Especially in such a fast-paced and high-stress living environment, eating disorders or overeating have further contributed to the increase of people with obesity. 1 The prevalence of obesity worldwide has shown a continuous increase over the past 50 years. According to a summary analysis of body mass indices of adolescents and children in various countries around the world from 1975 to 2016, the prevalence of obesity has increased in all countries, with some regional differences. 2 The prevalence of obesity is higher in females than in males. 3 Income level is positively correlated with the prevalence of obesity and overweight, and the prevalence of obesity in high-income countries increased significantly in the past, but the prevalence of obesity and overweight children in some high-income countries, such as the United States, Denmark, and Sweden, has gradually stabilized since 2000. Meanwhile, the prevalence of obesity in low- and middle-income countries has been on the rise. Even in India, where the prevalence of obesity among women of childbearing age is 5.1% and the prevalence of overweight is 15.5%, which is related to the level of urbanization and economic development. 2,4 Current trends suggest that by 2025 the global prevalence of adult obesity will reach 18% among men and 21% among women. 5 Obesity causes several complications such as hyperinsulinemia, disorders of lipid metabolism, nonalcoholic fatty liver, coronary artery disease, cardiovascular disease, various types of cancer and chronic kidney disease (CKD). 6–9 In recent years, with the increase in the people with obesity, obesity has also become an important cause of CKD. An analysis of data from a UK biobank showed that for every 0.06 increase in waist-to-hip ratio estimated using genetic methods, the risk of CKD would increase by 30%; and for every 5 kg/m2 increase in body mass index (BMI), the risk of CKD would increase by 50%. 10 In the UK, about one-third of CKD patients are associated with overweight or obesity. 11 Another 14-year cohort study from Korean adults showed that high baseline levels of BMI and waist-to-hip ratio were independent risk factors for the development of CKD, and obesity was associated with the incidence of CKD. 12 The fact that BMI is associated with obesity-related kidney injury is reflected in the assessment of the degree of obesity. However, BMI i -Abstract Truncated-
endocrinology & metabolism